NEUROCOGNITIVE DISORDER TREATMENT MARKET ANALYSIS
The clinical trials of some drugs are terminated, as they are not able to reach to their primary endpoint. For instance, on March 21, 2019, Biogen and Eisei, Co., Ltd announced the decision to discontinue the global phase 3 trial of Aducanumab, which is designed to evaluate the safety and efficacy of an antibody-aducanumab in patients with Alzheimer disease. This decision to stop the trial is based on the analysis that trials were unlikely to improve the people’s memory and thinking sufficiently by the end of the trial. This discontinuation of trials is the major restraining factor for the market.
RestaintsThe clinical trials of some drugs are terminated, as they are not able to reach to their primary endpoint. For instance, on March 21, 2019, Biogen and Eisei, Co., Ltd announced the decision to discontinue the global phase 3 trial of Aducanumab, which is designed to evaluate the safety and efficacy of an antibody-aducanumab in patients with Alzheimer disease. This decision to stop the trial is based on the analysis that trials were unlikely to improve the people’s memory and thinking sufficiently by the end of the trial. This discontinuation of trials is the major restraining factor for the market.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
